Latest Blogs, News & Events

Therigy makes University of Florida’s Gator100 List of the Fastest Growing Companies for Second Year

  February 23, 2016

Company Co-founder and President Joseph Morse, BA, class of 1995, accepted the honor in Gainesville

For the second year in a row, Therigy, LLC, the trusted source for consulting services and technology solutions for the specialty pharmaceutical market, has been named to the Gator100 -- a list of the 100 fastest-growing businesses in the world owned or led by University of Florida alumni.

Ernst & Young calculated each company’s compounded annual growth rate (CAGR) over the past three years to generate the ranking. Therigy came in at number 55, with a growth rate of 39 percent.

“We are thrilled to have been named to the Gator100 again this year,” company Co-founder and President Joseph Morse said. “It is humbling to receive this award and be among so many great companies that are making a difference in their respective industries. It is a special time to celebrate the milestones we’ve achieved and give thanks to our valued customers and great employees who have helped Therigy advance the specialty pharmaceutical market.”

More than 500 guests attended the Gator100 luncheon and awards ceremony. Former U.S. Senator and Florida Governor Bob Graham (BA ’59) was the keynote speaker at the event. During the event, Morse participated on a panel titled “Lonely at the Top: Getting Advice and Mentoring When Running a High Growth Venture.” He was joined by Scott Moss, President, Moss and Associates (number 91); Skye Perry, Founder and President, SSP Innovations (29); Bob Diener, Co-founder, and (92); and Deborah Garcia Gratacos, President, DEVAL (86). The panel was moderated by Marty Schaffel, Founder and CEO, Audio Visual Innovations.

In addition to the Gator100, Therigy is celebrating its tenth anniversary this year. Morse and Russel Allinson, CEO and Chief Clinical Officer, co-founded Therigy in 2006. Jon Hamrick, Executive Vice-President, an MBA graduate of Florida’s Warrington College of Business and long-term specialty pharmacy veteran, joined Therigy’s executive team in 2011. In addition to dramatic growth in revenue, Therigy has seen a large increase in staff and is on track to employ 70 to 100 people by the end of 2016.

The company’s signature product, TherigySTM, is used by more than 100 leading specialty pharmacies to provide superior care and therapy-specific clinical support to maximize adherence and improve patient outcomes. The application is used to manage the clinical care of more than 120,000 specialty patients across the U.S. and allows pharmacies to provide accurate and reliable data collection and outcomes reporting to its stakeholders. TherigySTM is integrated with pharmacy dispensing systems including EnterpriseRx by McKesson, PDX, Speed Script, CPR+, PioneerRx, Rx30, Opus-ISM, and others.

“This is an exciting time for our company and the specialty pharmacy industry as a whole,” Allinson said. “Therigy is proud to be one of the engines of economic development and job creation in Central Florida. I hope we can serve as a role model for other entrepreneurial companies.”


About Therigy
Therigy is the trusted source for innovative, best-in-class software and expert consulting services to the specialty pharmaceutical market. Clients leverage Therigy’s solutions, data, and insights to achieve clinical and economic success by aligning strategy, technology, and people.

About the Gator100
The Gator100, sponsored by the University of Florida, the Warrington College of Business and the Entrepreneurship & Innovation Center, recognizes and celebrates the achievements of leading UF alumni entrepreneurs around the world. The Gator100 ranks the 100 fastest-growing, Gator-owned or Gator-led businesses each year—regardless of which school or college the alumni graduated from—recognizing the entrepreneurial spirit in all Gator alumni across our campus.


Media inquiries, please contact:

Sara Wilson

Director, Marketing




Therigy  Partner with Therigy to conduct outcomes studies based on real-world evidence across 20+ specialty disease states and 400+ specialty medications.
Contact Us Today!